At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 92 enrolled
Drug / intervention
Roxadustatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Open Label Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
In Brief
A Phase 2 clinical trial evaluating Roxadustat for Chemotherapy Induced Anemia. Completed, enrolled 92 participants across 15 sites.
Detailed Summary
The purpose of this study is to find out if roxadustat (also known as FG-4592) is safe and effective for the treatment of anemia in participants receiving chemotherapy treatment for cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChemotherapy Induced Anemia
CountriesUnited States
CollaboratorsAstraZeneca, Astellas Pharma Inc
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartAug 2019
First PostedSep 2019
Primary CompletionMar 2021
Study CompletionApr 2021
TodayJul 2026
First PostedSep 4, 2019
Enrollment StartAug 20, 2019
Primary CompletionMar 26, 2021
Study CompletionApr 23, 2021
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.8 years ago
Interventions
Roxadustatdrug
Roxadustat will be administered per schedule specified in the arm description.